Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer

被引:70
作者
So, T [1 ]
Takenoyama, M [1 ]
Mizukami, M [1 ]
Ichiki, Y [1 ]
Sugaya, M [1 ]
Hanagiri, T [1 ]
Sugio, K [1 ]
Yasumoto, K [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Surg 2, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
关键词
D O I
10.1158/0008-5472.CAN-04-3787
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One of tumor escape mechanisms from the host's immunosurveillance system (i.e., a haplotype loss of HLA class I antigens) has been detected in various tumor cells. We hypothesize that the majority of tumor cells with normal HLA class 1 expression were attacked and eradicated by CTLs, and only a minority with an abnormal expression of HLA class 1 antigens could escape the host's immunosurveillance system. Using HLA class 1-transfected tumor variants as stimulators in A904L lung cancer cell line, which has a haplotype loss of YMA class 1 antigens, both the transfected HLA-A26 and HLA-B39-restricted CTL lines were induced from autologous lymphocytes. However, only one HLA-1339-restricted CTL clone (CTL G3b) was established, and it was then used to identify the antigen. SGT1B [suppressor of G2 allele of SKP1 (SGT1), suppressor of kinetochore protein (SKP1)] was identified as the antigen recognized by CTL G3b. Further experiments using 13 subclones from a primary culture of A904L were found to confirm our above-mentioned hypothesis. Tumor cells with a normal HLA class I expression may thus be killed by CTL at an early stage of carcinogenesis, and only tumor cells with a haplotype loss of HLA class I antigens can escape an immune attack and develop into clinical cancer.
引用
收藏
页码:5945 / 5952
页数:8
相关论文
共 39 条
[1]  
AZUMA M, 1992, J IMMUNOL, V149, P1115
[2]  
Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.3.CO
[3]  
2-E
[4]   Mechanisms of loss of HLA class I expression on colorectal tumor cells [J].
Browning, M ;
Petronzelli, F ;
Bicknell, D ;
Krausa, P ;
Rowan, A ;
Tonks, S ;
Murray, N ;
Bodmer, J ;
Bodmer, W .
TISSUE ANTIGENS, 1996, 47 (05) :364-371
[5]   High frequency of altered HLA class I phenotypes in invasive breast carcinomas [J].
Cabrera, T ;
Fernandez, MA ;
Sierra, A ;
Garrido, A ;
Herruzo, A ;
Escobedo, A ;
Fabra, A ;
Garrido, F .
HUMAN IMMUNOLOGY, 1996, 50 (02) :127-134
[6]  
Chatterjee A, 2001, CANCER RES, V61, P2119
[7]   LACK OF HLA CLASS-I ANTIGEN EXPRESSION BY CULTURED MELANOMA-CELLS FO-1 DUE TO A DEFECT IN B2M GENE-EXPRESSION [J].
DURSO, CM ;
WANG, ZG ;
CAO, Y ;
TATAKE, R ;
ZEFF, RA ;
FERRONE, S .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (01) :284-292
[8]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[9]   NATURAL-HISTORY OF HLA EXPRESSION DURING TUMOR-DEVELOPMENT [J].
GARRIDO, F ;
CABRERA, T ;
CONCHA, A ;
GLEW, S ;
RUIZCABELLO, F ;
STERN, PL .
IMMUNOLOGY TODAY, 1993, 14 (10) :491-499
[10]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95